Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Costs · overweight or obese adults Green tea for weight loss and weight maintenance in overweight or obese adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs placebo Pain · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs placebo Patient global assessment · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs placebo Health Related Quality of Life · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 120 mg/day vs placebo Pain · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 120 mg/day vs placebo Patient global assessment · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 120 mg/day vs placebo Health Related Quality of Life · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs allopurinol Pain · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs allopurinol Patient global assessment · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs allopurinol Health Related Quality of Life · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs placebo Pain · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs allopurinol Pain · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs allopurinol Patient global assessment · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs allopurinol Health Related Quality of Life · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 120 mg/day vs allopurinol Pain · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 120 mg/day vs allopurinol Patient global assessment · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs placebo Patient global assessment · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 120 mg/day vs allopurinol Health Related Quality of Life · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs placebo Health Related Quality of Life · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Clinically apparent hepatitis A ( · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Clinically apparent hepatitis A ( · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Hepatitis A‐related mortality · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Lack of sero‐protection, (anti HAV IgG < 10mIU/L) (low risk of bias) Maiwald 1997 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Lack of sero‐protection, (anti HAV IgG < 10mIU/L) (all included trials) Maiwald 1997 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Non‐serious local adverse events (low risk of bias) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Non‐serious local adverse events (all included studies) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Non‐serious systemic adverse events (low risk of bias) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Non‐serious systemic adverse events (all included studies) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Clinically apparent hepatitis A (live attenuated HAV vaccines) low risk of bias Dienstag 1999 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Clinically apparent hepatitis A (Dose of live attenuated HAV vaccine, titre >= TCID50 ) low risk of bias Dienstag 1999 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Clinically apparent hepatitis A (Dose of live attenuated HAV vaccine, titre < TCID50 ) low risk of bias Dienstag 1999 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Amitriptyline vs placebo Death due to suicide · adults with major depressive disorder Amitriptyline versus placebo for major depressive disorder (2012) · Cochrane | no estimate extracted | NR | No studies |
Amitriptyline vs placebo Quality of life · adults with major depressive disorder Amitriptyline versus placebo for major depressive disorder (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Proportion below 30/100 mm on VAS · painful diabetic neuropathy Lacosamide for neuropathic pain and fibromyalgia in adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life measure · painful diabetic neuropathy Lacosamide for neuropathic pain and fibromyalgia in adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone Serious adverse events · patients with primary CNS lymphoma Role of chemotherapy additional to high‐dose methotrexate for primary central nervous system lymphoma (PCNSL) (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · patients with type 2 diabetes mellitus Colesevelam for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mortality · patients with type 2 diabetes mellitus Colesevelam for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · patients with type 2 diabetes mellitus Colesevelam for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Functional outcomes · patients with type 2 diabetes mellitus Colesevelam for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Costs · patients with type 2 diabetes mellitus Colesevelam for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Ergonomic keyboard vs placebo Short‐term overall improvement ‐ not measured · people with carpal tunnel syndrome Ergonomic positioning or equipment for treating carpal tunnel syndrome (2012) · Cochrane | no estimate extracted | NR | No studies |
Ergonomic keyboard vs placebo Adverse effects ‐ not measured · people with carpal tunnel syndrome Ergonomic positioning or equipment for treating carpal tunnel syndrome (2012) · Cochrane | no estimate extracted | NR | No studies |
Ergonomic keyboard vs placebo Long‐term improvement in functional ability (> 3 months) ‐ not measured · people with carpal tunnel syndrome Ergonomic positioning or equipment for treating carpal tunnel syndrome (2012) · Cochrane | no estimate extracted | NR | No studies |
Motivational interviewing vs control Adherence ‐ not measured · patients with Improving outcomes in youth living with HIV Motivational interviewing for improving outcomes in youth living with HIV (2012) · Cochrane | no estimate extracted | NR | No studies |
Motivational interviewing vs control Mortality ‐ not measured · patients with Improving outcomes in youth living with HIV Motivational interviewing for improving outcomes in youth living with HIV (2012) · Cochrane | no estimate extracted | NR | No studies |
Motivational interviewing vs control Quality of life ‐ not measured · patients with Improving outcomes in youth living with HIV Motivational interviewing for improving outcomes in youth living with HIV (2012) · Cochrane | no estimate extracted | NR | No studies |
MAOIs vs placebo Physical function · patients with fibromyalgia syndrome Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome (2012) · Cochrane | no estimate extracted | NR | No studies |
MAOIs vs placebo Sleep disturbance · patients with fibromyalgia syndrome Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome (2012) · Cochrane | no estimate extracted | NR | No studies |
Sodium hypochlorite 5.25% with hydrogen peroxide 3% vs Normal saline Proportion of participants with new or worsening signs/symptoms of inflammation requiring a revisit, up to 14 days after the procedure · Patients aged 14 to 78 years with mature permanent teeth (fully formed roots), single or multi-rooted, with pulpal or… Irrigants for non‐surgical root canal treatment in mature permanent teeth (2012) · Cochrane | no estimate extracted | 0 studies | No studies |